Community Practice Connections™: 1st Annual Optometry Times® EyeCon 2021
February 22, 2022
February 22, 2023
Scroll to the Bottom of this Information to Begin this Course
This activity is provided by Physicians’ Education Resource®, LLC.
This activity is supported by educational grants from AbbVie Inc., Alcon Vision, LLC and Genentech, a member of the Roche Group.
- Physicians — maximum of 1.5 AMA PRA Category 1 Credit(s)™
All other healthcare professionals completing this course will be issued a statement of participation.
For Optometrists seeking COPE Credit, please click here: https://learning.freecme.com/a/39082P3uJsSS
This educational activity is directed toward optometrists who treat patients with both common and rare ocular conditions. Other health care professionals interested in the diagnosis and management of eye conditions are also invited to participate.
As the clinicians at the front lines of eye and vision care, doctors of optometry are tasked with diagnosing, treating, and managing ocular disorders and vision changes related to systemic disease. They also play a crucial role in educating their patients on ocular and visual health, since surveys show that 4 in 10 Americans do not know how to properly care for their eyes. A number of new and emerging diagnostic tools and therapies are changing the way ocular diseases are treated and can lead to better patient outcomes.
This Community Practice Connections™ program provides an in-depth review of some of the key highlights from the Optometry Times® EyeCon 2021 meeting, held in December 2021. This unique and engaging multimedia activity is ideal for the community-based clinician and focuses on the practical aspects of managing patients with eye conditions, putting recent clinical trial data into clinical context. The program is designed for those who did not attend the live meeting and to help reinforce learnings for those who did.
Upon successful completion of this activity, you should be better prepared to:
- Recommend diagnostic approaches to correctly identify early presentations of both common and rare ocular diseases
- Apply recent guidelines and other evidence to the diagnosis and management of patients with ocular conditions
- Demonstrate the ability to use emerging clinical trial data to optimize patient treatment in the optometry setting
- Determine the most appropriate approaches to improve vision outcomes and patient care in the office with new and emerging therapies and technologies
Paul Chous, OD, MA, FAAO
Chous Eye Care Associates
Adjunct Professor, Western University of Health Sciences
Danica J. Marrelli, OD, FAAO
University of Houston College of Optometry
Kelly K. Nichols, OD, PhD, MPH, FAAO
Dean and Professor
School of Optometry
The University of Alabama at Birmingham
President, Association of Schools and Colleges of Optometry
Ocular Surface Research Institute of the Clinical Eye Research Facility
Adam Ramsey, OD
Medical Director of Socialite Vision
Palm Beach Gardens, FL
Jessica Steen, OD, FAAO
Diplomate, American Board of Optometry
Nova Southeastern University
College of Optometry
Fort Lauderdale, FL
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.
- Paul Chous, OD, MA, FAAO
- Consultant: ZeaVision, VSP Vision Care, Zeiss, Regeneron, EyeNuk, AI Optics
- Speakers Bureau: VSP Vision Care, Regeneron, EyePromise
- Danica J. Marrelli, OD, FAAO
- Consultant: Allergan, Bausch + Lomb, Aerie Pharmaceuticals, Carl Zeiss Meditec, Ivantis, Sun Ophthalmics
- Speakers Bureau: Bausch + Lomb, Aerie Pharmaceuticals, Carl Zeiss Meditec
- Kelly K. Nichols, OD, PhD, MPH, FAAO
- Grant/Research Support: Allergan, Kala, and Tear Science
- Consultant: Allergan/AbbVie, Aerie Pharmaceuticals, Axim Biotech, Bruder Healthcare Co. LLC, Bausch + Lomb, Dompé, HanAll Biopharma, Kala Pharmaceuticals, Novartis, Osmotica/RVL Pharmaceuticals, Oyster Point Pharma, Sight Sciences, Tear Film Innovations/Alcon, Théa, Tarsus Pharmaceuticals, TearSolutions, TopiVert Pharma, Visionology, and Yuyu Pharma Inc.
- Other: Jason J. Nichols, OD, PhD, MPH, FAAO is the spouse of Kelly K. Nichols, OD, PhD, MPH, FAAO, extending his declarations to her, consultation from Alcon, research from NIH NEI.
Adam Ramsey, OD has no relevant financial relationships with ineligible companies.
Jessica Steen, OD, FAAO has no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Instructions for Participation and Credit
- Complete the activity (including pre- and post-activity assessments).
- Answer the evaluation questions.
- Request credit using the drop-down menu.
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.